165 related articles for article (PubMed ID: 16264107)
1. Efficacy of ibandronate in metastatic bone disease: review of clinical data.
Bell R
Oncologist; 2005; 10 Suppl 1():8-13. PubMed ID: 16264107
[TBL] [Abstract][Full Text] [Related]
2. Renal safety of ibandronate.
Jackson GH
Oncologist; 2005; 10 Suppl 1():14-8. PubMed ID: 16264108
[TBL] [Abstract][Full Text] [Related]
3. Ibandronate: its role in metastatic breast cancer.
Cameron D; Fallon M; Diel I
Oncologist; 2006; 11 Suppl 1():27-33. PubMed ID: 16971737
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonate treatment recommendations for oncologists.
von Moos R
Oncologist; 2005; 10 Suppl 1():19-24. PubMed ID: 16264109
[TBL] [Abstract][Full Text] [Related]
5. Ibandronate: efficacy in the treatment of metastatic bone disease.
Diel IJ
Future Oncol; 2005 Oct; 1(5):593-607. PubMed ID: 16556036
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
[TBL] [Abstract][Full Text] [Related]
7. Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials.
Tripathy D; Body JJ; Bergström B
Clin Ther; 2004 Dec; 26(12):1947-59. PubMed ID: 15823760
[TBL] [Abstract][Full Text] [Related]
8. Ibandronate in metastatic bone pain.
Heidenreich A; Ohlmann C; Body JJ
Semin Oncol; 2004 Oct; 31(5 Suppl 10):67-72. PubMed ID: 15490379
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates for malignancy-related bone disease: current status, future developments.
Body JJ
Support Care Cancer; 2006 May; 14(5):408-18. PubMed ID: 16450087
[TBL] [Abstract][Full Text] [Related]
10. Oral ibandronate in metastatic bone breast cancer: the Florence University experience and a review of the literature.
Meattini I; Bruni A; Scotti V; Livi L; De Luca Cardillo C; Galardi A; Cipressi S; Biti G
J Chemother; 2010 Feb; 22(1):58-62. PubMed ID: 20227995
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
12. Managing metastatic bone pain: the role of bisphosphonates.
Gralow J; Tripathy D
J Pain Symptom Manage; 2007 Apr; 33(4):462-72. PubMed ID: 17397707
[TBL] [Abstract][Full Text] [Related]
13. Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer.
Heras P; Karagiannis S; Kritikos K; Hatzopoulos A; Mitsibounas D
Eur J Cancer Care (Engl); 2007 Nov; 16(6):539-42. PubMed ID: 17944770
[TBL] [Abstract][Full Text] [Related]
14. Preclinical and clinical efficacy of the bisphosphonate ibandronate in cancer treatment.
Bauss F; Bergström B
Curr Clin Pharmacol; 2008 Jan; 3(1):1-10. PubMed ID: 18690873
[TBL] [Abstract][Full Text] [Related]
15. Bone pain reduction in patients with metastatic breast cancer treated with ibandronate-results from a post-marketing surveillance study.
Diel IJ; Kurth AH; Sittig HB; Meden H; Maasberg M; Sandermann A; Bergner R
Support Care Cancer; 2010 Oct; 18(10):1305-12. PubMed ID: 20151162
[TBL] [Abstract][Full Text] [Related]
16. [The role of ibandronate in the daily oncological practice].
Nagykálnai T
Magy Onkol; 2006; 50(4):325-7. PubMed ID: 17216006
[TBL] [Abstract][Full Text] [Related]
17. Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease.
Coleman RE; Purohit OP; Black C; Vinholes JJ; Schlosser K; Huss H; Quinn KJ; Kanis J
Ann Oncol; 1999 Mar; 10(3):311-6. PubMed ID: 10355575
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study.
Mancini I; Dumon JC; Body JJ
J Clin Oncol; 2004 Sep; 22(17):3587-92. PubMed ID: 15337809
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer: bisphosphonate therapy for metastatic bone disease.
Body JJ
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6258s-6263s. PubMed ID: 17062710
[TBL] [Abstract][Full Text] [Related]
20. Ibandronate: its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease.
Heidenreich A; Ohlmann CH
Expert Rev Anticancer Ther; 2004 Dec; 4(6):991-1005. PubMed ID: 15606328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]